Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study.
Thirty-nine patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with mitoxantrone (dihydroxyanthracenedione hydrochloride). Twenty-five patients were started at a dose of 12 mg/m2 q 21d and 13 patients, with compromised bone marrow, at a dose of 10 mg/m2 q 21d. Two stable responses (6%) occurred in 31 fully evaluable patients. The median duration of survival was 17 weeks. The principal toxicity, hematopoietic (primarily leukopenia), was mild and well tolerated. We conclude that mitoxantrone is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.
D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D008942:Mitoxantrone; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies
D000880:Anthraquinones; D008942:Mitoxantrone